1. Home
  2. LNAI vs LSTA Comparison

LNAI vs LSTA Comparison

Compare LNAI & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LNAI
  • LSTA
  • Stock Information
  • Founded
  • LNAI N/A
  • LSTA 1980
  • Country
  • LNAI United States
  • LSTA United States
  • Employees
  • LNAI N/A
  • LSTA N/A
  • Industry
  • LNAI Biotechnology: Pharmaceutical Preparations
  • LSTA Misc Health and Biotechnology Services
  • Sector
  • LNAI Health Care
  • LSTA Health Care
  • Exchange
  • LNAI Nasdaq
  • LSTA Nasdaq
  • Market Cap
  • LNAI 23.9M
  • LSTA 20.9M
  • IPO Year
  • LNAI N/A
  • LSTA N/A
  • Fundamental
  • Price
  • LNAI $1.25
  • LSTA $1.96
  • Analyst Decision
  • LNAI
  • LSTA Strong Buy
  • Analyst Count
  • LNAI 0
  • LSTA 2
  • Target Price
  • LNAI N/A
  • LSTA $23.50
  • AVG Volume (30 Days)
  • LNAI 9.2M
  • LSTA 146.9K
  • Earning Date
  • LNAI 11-14-2025
  • LSTA 11-06-2025
  • Dividend Yield
  • LNAI N/A
  • LSTA N/A
  • EPS Growth
  • LNAI N/A
  • LSTA N/A
  • EPS
  • LNAI N/A
  • LSTA N/A
  • Revenue
  • LNAI N/A
  • LSTA $1,070,000.00
  • Revenue This Year
  • LNAI N/A
  • LSTA N/A
  • Revenue Next Year
  • LNAI N/A
  • LSTA N/A
  • P/E Ratio
  • LNAI N/A
  • LSTA N/A
  • Revenue Growth
  • LNAI N/A
  • LSTA N/A
  • 52 Week Low
  • LNAI $0.81
  • LSTA $1.85
  • 52 Week High
  • LNAI $21.00
  • LSTA $4.20
  • Technical
  • Relative Strength Index (RSI)
  • LNAI N/A
  • LSTA 34.03
  • Support Level
  • LNAI N/A
  • LSTA $1.92
  • Resistance Level
  • LNAI N/A
  • LSTA $2.13
  • Average True Range (ATR)
  • LNAI 0.00
  • LSTA 0.19
  • MACD
  • LNAI 0.00
  • LSTA -0.03
  • Stochastic Oscillator
  • LNAI 0.00
  • LSTA 22.70

About LNAI Lunai Bioworks Inc. Common Stock

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.

Share on Social Networks: